Phathom Pharmaceuticals Inc (NAS:PHAT)

Q4 2024 Phathom Pharmaceuticals Inc Earnings Call Transcript

Mar 6, 2025 / 01:30 PM GMT

Release Date Price: $5.9 (-2.96%)

Transcript 8-K10-K

Key Points

Positve

Phathom Pharmaceuticals Inc (PHAT) secured FDA approval for non-erosive GERD, enhancing their product portfolio.
The company reported strong commercial coverage, with over 120 million lives covered, facilitating access to their product.
Phathom Pharmaceuticals Inc (PHAT) achieved over 300,000 prescriptions filled, indicating strong market demand.
The company is investing in a new consumer campaign to increase brand awareness and drive growth.
Phathom Pharmaceuticals Inc (PHAT) ended the year with $297 million in cash, providing a solid financial foundation for future investments.

Negative

Phathom Pharmaceuticals Inc (PHAT) anticipates a softened first quarter in 2025 due to industry-wide seasonal dynamics.
The company faces limited Medicare and Medicaid coverage, which could restrict access for some patients.
There is uncertainty surrounding the FDA's decision on their citizen petition, which could impact regulatory exclusivity.
Phathom Pharmaceuticals Inc (PHAT) reported a GAAP net loss of $74.5 million for the fourth quarter of 2024.
The company expects increased R&D and SG&A expenses in 2025, which could pressure profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAT.OQ - Phathom Pharmaceuticals Inc
Q4 2024 Phathom Pharmaceuticals Inc Earnings Call
Mar 06, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the Fathom Pharmaceuticals 4th quarter and full year 2024 earnings results call.

At this time, all participants are in a listen-only mode.

After the presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone.

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please be advised that today's call is being recorded.

With that, I would like to turn the conference over to Eric Shirili, Fathom's head of investor relations. Please go ahead.

----------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.